港股生物制药板块今日普遍走高,其中艾美疫苗(06660)股价特别抢眼,盘中一度大涨逾24%。分析人士指出,该股大涨主要受到两方面利好因素的推动。
首先是行业板块的整体向好。在医药生物类股票领涨带动下,同板块内艾美疫苗等个股随之获得资金追捧。除艾美疫苗外,中国再生医学、和黄医药、康方生物等生物制药股也实现了两位数以上的大涨。
另一方面,艾美疫苗公司自身的利好消息也是股价大涨的主因。艾美疫苗最新发布公告称,旗下在研迭代无血清狂苗Ⅲ期临床试验数据已完成揭盲及统计分析工作,结果显示该疫苗具有良好的免疫原性和安全性,达到临床预设目标。这意味着该无血清狂苗有望成为全球首个上市的该类疫苗,引领行业技术深度迭代升级。相比目前市场上的含血清狂苗,无血清狂苗不含动物血清,显著提高了安全性并降低不良反应概率,因此属于一款重磅创新产品。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.